Dr Kiuru group’s expertise in marine-derived compounds adds a unique dimension to the consortium's capabilities. Here's how Dr Kiuru's involvement can strengthen the chemistry pole:

Diversification of Compound Sources: Dr Kiuru's access to compounds derived from marine sources introduces a novel avenue for drug discovery within the consortium. Marine organisms are rich sources of bioactive molecules with diverse chemical structures and pharmacological properties. By tapping into this resource, the consortium can explore a broader range of compound classes with potential applications in targeting ion channels.

Enhanced Chemical Diversity: The compounds derived from marine sources often exhibit unique chemical scaffolds not commonly found in terrestrial organisms. Integrating these compounds into the consortium's chemical library expands the diversity of molecules available for screening and optimization. This diversity increases the likelihood of identifying lead compounds with desirable pharmacological profiles for targeting ion channels involved in cancer biology.

Complementary Expertise: Dr Kiuru's expertise in marine natural product chemistry complements the capabilities of Lucija's group in synthetic chemistry and medicinal chemistry. Combining their knowledge and resources, the consortium gains a comprehensive understanding of compound synthesis, optimization, and biological evaluation for ion channel targeting. This collaboration enhances the consortium's ability to develop innovative therapeutic agents for cancer treatment.
Overall, Dr Kiuru's collaboration with Pr Lucija Peterlin Mašič's group strengthens the consortium's chemistry pole by enriching its compound library with marine-derived molecules and leveraging complementary expertise in compound synthesis and optimization.